Shares of Personalis (PSNL) surged 5.24% in after-hours trading on Tuesday, following a series of bullish analyst reports and a notable price target increase. The genomic sequencing company's stock received a boost as multiple firms reaffirmed their positive outlook on the company's prospects.

H.C. Wainwright & Co. led the charge by raising its price target on Personalis to $13 from $10, while maintaining a Buy rating. This significant increase in the price target suggests growing confidence in the company's future performance. Additionally, both Guggenheim and BTIG reiterated their Buy ratings on the stock, further solidifying the positive sentiment among analysts.

While Morgan Stanley maintained its Equal-Weight rating on Personalis, the overall bullish stance from other prominent research firms appears to have overshadowed this neutral position. The collective positive analyst sentiment, particularly the raised price target, likely contributed to investors' enthusiasm, driving the stock's after-hours rally.